MedTrace Logo

Prevalence and Characteristics of Intimate Partner Violence Against Individuals Seeking Hematological Consultations

NCT06415968 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 138

Last updated 2025-02-18

No results posted yet for this study

Summary

Intimate violence against individuals, which is particularly marked among women, is one of the most widespread human rights violations in the world.

The Women Abuse Screening Tool (WAST) self-questionnaire is a screening tool validated in French.

Our preliminary data describing the association between intimate violence against women and the first attack of unexplained venous thromboembolic disease, show a significant frequency of positive responses to the WAST among women attending a biological hematology consultation at the CHU de Nîmes, for reasons of hemostasis disorders (8% out of the first 200 cases).

The study authors wish to establish the prevalence of this situation among patients presenting to the CHU de Nîmes for hematological exploration and management. They hypothesize that the prevalence of violence against individuals seen in Hematology consultations is higher among individuals with hemostasis pathologies (hemorrhagic and thrombotic pathologies) than those with cellular pathologies, and higher among women than men.

Conditions

  • Intimate Partner Violence
  • Deep Vein Thrombosis (DVT)/Thrombophlebitis
  • Pulmonary Embolism and Thrombosis

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Jean-Christophe Gris · CHU de Nimes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-10
Primary Completion
2025-02-11
Completion
2025-02-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06415968 on ClinicalTrials.gov